{"entity":{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","aka":["340B","340B programme","340B program","340B discounts","Veterans Health Care Act of 1992"],"tldr":"A US law that lets certain hospitals buy outpatient drugs, including cancer drugs, at deep discounts. Controversial because hospitals may bill insurers full price.","summary":"United States, federal statute. Section 340B of the Public Health Service Act was created by the Veterans Health Care Act of 1992 (Public Law 102-585) and is administered by the Health Resources and Services Administration. Primary text: the HRSA 340B pages link the statute and guidance.\n\nEnacted 1992; covered entities (disproportionate-share hospitals, federally qualified health centres) receive manufacturer discounts of 25-50%. It shapes where oncology infusions happen (hospital outpatient vs community practice), fuels hospital acquisition of oncology practices, and is under litigation and legislative pressure over contract pharmacies and rebate models.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/340B_Drug_Pricing_Program","links":[{"label":"HRSA 340B","url":"https://www.hrsa.gov/opa"}],"tags":[],"related":["inflation-reduction-act","hatch-waxman","bpcia","medicare-ced","drug-price-transparency","financial-toxicity","hta"],"cancers":[],"sections":[],"technologies":["community-oncology-networks"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/340b-program/","neighbours":{"term":[{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/"},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/"}],"technology":[{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/"}],"idea":[{"id":"idea-cost-340b-pass-through","kind":"idea","name":"Pass 340B discounts on cancer drugs through to the patient's bill","route":"/ideas/idea-cost-340b-pass-through/"},{"id":"idea-cost-asp-flat-fee","kind":"idea","name":"Pay a flat fee for giving a Part B drug instead of 6% of its price","route":"/ideas/idea-cost-asp-flat-fee/"},{"id":"idea-cost-site-neutral-infusion","kind":"idea","name":"Pay the same for an infusion whether it is given in a hospital or a clinic","route":"/ideas/idea-cost-site-neutral-infusion/"}]}}